Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBM Group Promotes Mail Order Savings, Vows Differential Co-Pays

Executive Summary

Mail-order pharmacies could capture as much as half of the total prescription drug market if consumers applied the service to all appropriate scripts, The Lewin Group concludes in a report to PCMA

You may also be interested in...



Mail-Order Pharmacy Not Necessarily Cheaper To Health Plans, Ohio Finds

Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago

Mail-Order Pharmacy Not Necessarily Cheaper To Health Plans, Ohio Finds

Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago

Formulary Payments From Manufacturers To PBMs Reviewed By FTC

Contract agreements between pharmacy benefit managers and pharmaceutical manufacturers do not typically demonstrate higher payment allowances for drugs dispensed through PBM-owned mail order pharmacies compared to retail pharmacies, according to a Federal Trade Commission report

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel